Ligand looking to future deals around protein expression platform with Pfenex takeout

Ligand is adding to its stable of drug discovery technologies to partner with biopharmas through its acquisition of Pfenex and its protein expression platform.

The deal is the largest acquisition by Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to date, which over the past five years has been doing smaller deals to add technologies to its services and partnering business...